atuzabrutinib   Click here for help

GtoPdb Ligand ID: 11666

Synonyms: compound 11 [PMID: 35302767] | PRN-473 | PRN473 | SAR-444727 | SAR444727
Compound class: Synthetic organic
Comment: Atuzabrutinib (PRN473) is a Bruton's tyrosine kinase inhibitor [2]. The chemical structure was obtained from WHO Proposed list 125. Atuzabrutinib's structure matches example 125A as claimed in Principia Biopharma's patent US9090621B2 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 122.95
Molecular weight 539.24
XLogP 5.82
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#C/C(=C\C(C)(C)C)/C(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1ccc(cc1F)Oc1ccccc1
Isomeric SMILES Nc1c2c(ncn1)n(nc2c1c(cc(cc1)Oc1ccccc1)F)[C@H]1CN(CCC1)C(=O)/C(=C/C(C)(C)C)/C#N
InChI InChI=1S/C30H30FN7O2/c1-30(2,3)15-19(16-32)29(39)37-13-7-8-20(17-37)38-28-25(27(33)34-18-35-28)26(36-38)23-12-11-22(14-24(23)31)40-21-9-5-4-6-10-21/h4-6,9-12,14-15,18,20H,7-8,13,17H2,1-3H3,(H2,33,34,35)/b19-15+/t20-/m1/s1
InChI Key KZMQPYCXSAGLTB-ZWUNQBBJSA-N
No information available.
Summary of Clinical Use Click here for help
PRN473 has progressed to clinical evaluation as a topical treatment for atopic dermatitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04992546 Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis Phase 2 Interventional Sanofi